Jazz Pharmaceuticals plc (JAZZ) said that its Co-Founder, Chairperson and Chief Executive Officer, Bruce Cozadd, plans to retire from his role as Chief Executive Officer upon appointment of the Company's next leader, expected by the end of 2025. Cozadd will continue serving as Chairperson of the Board of Directors.
The Board will commence a formal search process to identify a new Chief Executive Officer, which is anticipated to conclude within 12 months.
Jazz said it remains on track to meet its full year 2024 total revenue guidance of between $4.0 billion and $4.1 billion. Analysts polled by Thomson Reuters expect the company to report revenues of $4.04 billion for fiscal year 2024. Analysts' estimates typically exclude special items.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.